Nasopharyngeal carcinoma: tumor PD-L1 expression predicts poor survival

  • Cao Y & al.
  • BMC Cancer
  • 29 Oct 2019

  • curated by Brian Richardson, PhD
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Tumor expression of PD-L1 is associated with reduced OS and PFS in patients with nasopharyngeal carcinoma (NPC).

Why this matters

  • Prognostic factors can help guide patient management.

Key results

  • PD-L1 expression was detected in 87.6% of biopsy tissue.
  • 11.0% of patients had 0% PD-L1 expression, 14.3% of patients had 1%-5% PD-L1 expression, 47.4% had 5%-49% PD-L1 expression, and 26% had ≥50% PD-L1 expression.
  • In survival analysis, PD-L1 expression ≥50% was associated with reduced OS (P<.001 and pfs compared with pd-l1 expression style="list-style-type:circle;">
  • PD-L1 expression was associated with OS in multivariate analysis (HR, 2.361; P<.001>
  • BRAF mutation was associated with reduced PFS (P=.044 in survival analysis; P=.035 in Fisher’s exact test).
    • BRAF status was not associated with OS in multivariate analysis (HR, 1.349; P=.218).
  • Study design

    • 154 patients with NPC who received standard treatment, including radiation therapy with or without chemotherapy, were included.
    • Funding: Science and Technology Development Fund of Macau.

    Limitations

    • Retrospective study.
    • No multivariate analysis of PFS.